{"product_id":"reactine-5-mg-120-mg-6-compresse-rilascio-prolungato","title":"Reactine 5 mg + 120 mg 6 prolonged release tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eREACTINE is indicated in the short-term symptomatic treatment of seasonal and\/or perennial allergic rhinitis with nasal congestion and hypersecretion, nasal and\/or ocular itching, sneezing and tearing.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne tablet contains: • active ingredient: - cetirizine dihydrochloride 5 mg; - pseudoephedrine hydrochloride 120 mg. • excipient with known effects: lactose, sodium. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eFirst layer excipients\u003c\/i\u003e Hypromellose, microcrystalline cellulose, anhydrous colloidal silica, magnesium stearate. \u003ci\u003eSecond layer excipients \u003c\/i\u003e Lactose, microcrystalline cellulose, crosscaramellose sodium, colloidal anhydrous silica, magnesium stearate. \u003ci\u003eCoating excipients \u003c\/i\u003e Opadry Y-1-7000 white (methocel E5, premium (hypromellose) (E 464), titanium dioxide (E 171), macrogol 400).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eREACTINE is contraindicated in the following cases: • hypersensitivity to the active ingredients, to any of the excipients listed in paragraph 6.1, to hydroxyzine or piperazine derivatives; • severe renal insufficiency (patients with creatinine clearance less than 10 ml\/min); • severe hypertension; • severe coronary heart disease; • pheochromocytoma; • history of stroke; • high risk of developing hemorrhagic stroke; • serious arrhythmia; • uncontrolled hyperthyroidism; • patients who are being treated or who have been treated in the previous two weeks with monoamine oxidase inhibitors (see section 4.5); • patients who are being treated with dihydroergotamine; • increased intraocular pressure; • urinary retention; • children under 12 years old; • pregnancy and breastfeeding (see section 4.6).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e \u003cb\u003eAdults and children aged 12 and over\u003c\/b\u003e: one tablet 2 times a day, one in the morning and one in the evening, to be taken without chewing during or between meals. The duration of treatment should not exceed the period of acute symptoms and in any case should not be continued beyond 7 days. After 7 days of therapy, continue treatment with cetirizine alone. \u003cu\u003eSpecial populations\u003c\/u\u003e \u003ci\u003eElderly patients\u003c\/i\u003e The dose should be halved in elderly patients. \u003ci\u003ePatients with renal impairment\u003c\/i\u003e The dose should be halved in patients with renal insufficiency. \u003ci\u003ePatients with hepatic impairment\u003c\/i\u003e The dose should be halved in patients with hepatic impairment. \u003ci\u003ePediatric population \u003c\/i\u003e REACTINE is contraindicated in children under 12 years of age (see section 4.3). \u003cu\u003eMethod of administration\u003c\/u\u003e Oral use. The tablets should be taken with a little water and should not be divided, chewed or crushed.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo special precautions for storage.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eREACTINE is intended for short-term treatments only. Reactine must be used under medical supervision in diabetic patients and in subjects with thyroid problems, prostatic hypertrophy, hepatic insufficiency or reduced renal function, positive history of bronchospasm, as well as in elderly subjects. This medicine should be used under medical supervision in patients with pre-existing cardiovascular problems, including those with a history of myocardial infarction, coronary artery disease, hypertension, tachycardia and arrhythmia. Caution must also be exercised in subjects treated with sympathomimetics (decongestants, anorectics, psychostimulants) such as amphetamines, antihypertensive medicines, tricyclic antidepressants and digitalis or following the intake of higher quantities of alcohol or other substances with a depressant action on the central nervous system (CNS). Although at therapeutic doses of cetirizine, no clinically significant interactions with alcohol have been demonstrated (for a blood alcohol level of 0.5 g\/l), caution is recommended if alcohol is taken simultaneously. Caution should also be exercised in patients with risk factors that may increase the risk of haemorrhagic stroke (such as concomitant use of vasoconstrictors such as bromocriptine, pergolide, lisuride, cabergoline, ergotamine) or any other drug with decongestant activity (for example phenylpropanolamine, phenylephrine, ephedrine), used orally or nasally, due to the risk of vasoconstriction and increase in blood pressure (see paragraph 4.5). Increased ectopic pacemaker activity may occur when pseudoephedrine is used concomitantly with cardiac glycosides, such as digoxin or digitoxin; the use of the combination of cetirizine and pseudoephedrine should therefore be avoided in patients treated with cardiac glycosides (see section 4.5). Pseudoephedrine is associated with the risk of abuse. High doses may eventually induce toxicity. Prolonged use may induce habituation with an increased risk of overdose. Rapid discontinuation can induce depression. Use caution in patients with predisposing factors for urinary retention (e.g., spinal cord injury, prostatic hyperplasia), as cetirizine may increase the risk of urinary retention. Caution is recommended in patients at risk of hypercoagulation such as in inflammatory bowel disease, due to the vasoconstrictor effect of pseudoephedrine. Isolated cases of ischemic colitis have been reported in association with pseudoephedrine. The product should be discontinued in case of sudden abdominal pain, rectal bleeding or other symptoms of ischemic colitis. Caution is required in hypertensive patients receiving concomitant treatment with non-steroidal anti-inflammatory drugs (NSAIDs) as both pseudoephedrine and NSAIDs can increase blood pressure (see section 4.5). Severe skin reactions such as acute generalized exanthematous pustulosis (AGEP) may occur with medicines containing pseudoephedrine. This acute pustular eruption can occur within the first 2 days of treatment, with fever, and numerous small pustules, mostly non-follicular, resulting from a widespread edematous erythema and localized mainly on the skin folds, trunk and upper limbs. Patients should be carefully monitored. If signs and symptoms such as pyrexia, erythema or numerous small pustules are observed, the administration of Reactine should be stopped and appropriate measures taken if necessary. The medicine can act as a brain stimulant and give rise to episodes of insomnia, nervousness, hyperpyrexia, tremor and epileptic-type convulsions. During treatment with indirect sympathomimetic agents, acute postoperative hypertension may occur if they are used halogenated volatile anesthetics. Therefore, if surgery is planned, it is advisable to stop treatment 24 hours before anesthesia. Ischemic optic neuropathy Cases of ischemic optic neuropathy have been reported with pseudoephedrine. Pseudoephedrine should be discontinued if sudden loss of vision or reduction in visual acuity occurs, for example in the case of a scotoma. Allergy skin tests are inhibited by antihistamines therefore a washout period (3 days) is required before performing them. Athletes should be informed that treatment with pseudoephedrine could lead to a positive doping test result. If symptoms persist or worsen, or if new symptoms occur, discontinue use and consult a doctor. \u003cu\u003ePediatric population\u003c\/u\u003e \u003cu\u003eThe combination of cetirizine and pseudoephedrine is contraindicated in children under 12 years of age (see sections 4.2 and 4.3) due to the presence of pseudoephedrine and because this combination has not been studied in this age group\u003c\/u\u003e. \u003cu\u003eExcipient with known effects\u003c\/u\u003e The medicine contains lactose: patients suffering from rare hereditary problems of galactose intolerance, lactase deficiency, or glucose-galactose malabsorption should not take this medicine. This medicinal product contains less than 1 mmol (23 mg) sodium per single dose and can therefore be considered essentially sodium-free.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDue to the pharmacokinetic, pharmacodynamic and tolerability profile of cetirizine, no interactions are expected with this antihistamine. In reality, no significant pharmacodynamic or pharmacokinetic interactions were reported in drug-drug interaction studies carried out, in particular, with pseudoephedrine or theophylline (400 mg\/day). The activity of sympathomimetic amines such as pseudoephedrine contained in this medicinal product is increased by the concomitant administration of monoamine oxidase inhibitors and β-blockers. Due to the long duration of action of monoamine oxidase inhibitors, the activity of sympathomimetic amines can be observed even 15 days after discontinuation of administration (see section 4.3). Sympathomimetic amines reduce the antihypertensive effects of β-blockers, methyldopa, guanethidine, and reserpine. Antacids increase the absorption of pseudoephedrine while it is reduced by the simultaneous intake of kaolin. Concomitant administration of linezolid and pseudoephedrine may cause an increase in blood pressure in normotensive patients. Caution is also required in patients taking: - sympathomimetic drugs such as decongestants (e.g. phenylpropanolamine, phenylephrine, ephedrine), anorectics, psychostimulants such as amphetamines (combined effects on the cardiovascular system), - antihypertensive drugs (reduction of antihypertensive effects), - bromocriptine, pergolide, lisuride, cabergoline, ergotamine (risk of vasoconstriction and increase in blood pressure (see section 4.4), - tricyclic antidepressants, - alcohol or other substances with depressant action on the central nervous system (CNS) (possible intensification of the depressant action on the CNS and deterioration of performance), - cardiac glycosides such as digoxin or digitoxin (risk of cardiac arrhythmia) (see section 4.4), - non-steroidal anti-inflammatories (NSAIDs) (both pseudoephedrine and NSAIDs can increase blood pressure) (see section 4.4). The degree of absorption of cetirizine is not reduced by food intake, although the percentage of absorption is decreased.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eClinical studies have shown that cetirizine at a dose of 10 mg has minor side effects on the central nervous system, including drowsiness, fatigue, dizziness and headache. In some cases, paradoxical CNS stimulation has been reported. The following adverse reactions were reported by ≥ 1% of adult subjects in randomized, placebo-controlled trials with cetirizine alone: ​​drowsiness, nervousness, fatigue, dry mouth, dizziness, headache, nausea, pharyngitis, abdominal pain. Drowsiness was mild to moderate in the majority of cases, although statistically more common than with placebo. Further studies in which objective tests were carried out have shown that usual daily activities are not compromised at the recommended daily dose in healthy young volunteers. Although cetirizine is a selective H\u003csub\u003e1\u003c\/sub\u003e-peripheral and is relatively devoid of anticholinergic activity, cases of dysuria, accommodation disorder and dry mouth have been reported. Cases of abnormal liver function with elevations in liver enzymes accompanied by elevated bilirubin have been reported. This mainly resolves with discontinuation of treatment with cetirizine dihydrochloride. Isolated cases of stroke and ischemic colitis associated with the use of pseudoephedrine have been described in the literature. The following adverse reactions were reported by ≥ 1% of subjects in randomized, placebo-controlled trials with pseudoephedrine alone: ​​dry mouth, nausea, dizziness, insomnia, and nervousness. \u003cb\u003eClinical studies \u003c\/b\u003e The safety of the combination of cetirizine and pseudoephedrine from clinical studies is based on data from 3 randomized double-blind placebo-controlled studies for the treatment of seasonal allergic rhinitis. Table 1 includes adverse reactions that occurred in patients in whom more than one event was reported, and the incidence was higher than placebo and in 1% or more of patients. \u003cb\u003eTable 1: Side effects reported by \u003e 1% of adult subjects treated with the combination of cetirizine and pseudoephedrine in 3 randomized placebo-controlled clinical trials.\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eSystem Organ Classification: Cetirizine 5 mg\/Pseudoephedrine 120 mg Multi-dose (N =840) Placebo (N =831).\u003c\/p\u003e\n\u003cp\u003ePreferred Term: % (frequency) % (frequency).\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003eAsthenia: 2.0 (Common) 0.7 (Uncommon).\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders.\u003c\/p\u003e\n\u003cp\u003eDry mouth: 3.3 (Common) 0.4 (Uncommon).\u003c\/p\u003e\n\u003cp\u003eNervous system disorders.\u003c\/p\u003e\n\u003cp\u003eDizziness: 1.1 (Common) 0.1 (Uncommon).\u003c\/p\u003e\n\u003cp\u003eInsomnia: 3.8 (Common) 0.5 (Uncommon).\u003c\/p\u003e\n\u003cp\u003eDrowsiness: 2.5 (Common) 0.2 (Uncommon).\u003c\/p\u003e\n\u003cp\u003eSide effects observed and reported during treatment with REACTINE are reported according to system organ class according to MedDRA. Frequencies are defined as follows: • Very common (≥ 1\/10); • Common (≥ 1\/100, \u003c 1\/10); • Uncommon (≥ 1\/1,000, \u003c 1\/100); • Rare (≥ 1\/10,000, \u003c1\/1,000); • Very rare (\u003c1\/10,000); • Not known (frequency cannot be estimated from the available data).\u003c\/p\u003e\n\u003cp\u003eTable 2. Adverse reactions identified during post-marketing experience with cetirizine, pseudoephedrine or the combination of cetirizine and pseudoephedrine by frequency category estimated from spontaneous reporting *.\u003c\/p\u003e\n\u003cp\u003eSOCFrequency: Adverse reaction.\u003c\/p\u003e\n\u003cp\u003ePathologies of the blood and lymphatic system:\u003c\/p\u003e\n\u003cp\u003eVery rare: thrombocytopenia.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders:\u003c\/p\u003e\n\u003cp\u003eRare: Hypersensitivity (including anaphylactic shock).\u003c\/p\u003e\n\u003cp\u003eMetabolism and nutrition disorders:\u003c\/p\u003e\n\u003cp\u003eNot known: increased appetite.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders:\u003c\/p\u003e\n\u003cp\u003eCommon: nervousness.\u003c\/p\u003e\n\u003cp\u003eUncommon: anxiety.\u003c\/p\u003e\n\u003cp\u003eUncommon: agitation.\u003c\/p\u003e\n\u003cp\u003eRare: hallucinations.\u003c\/p\u003e\n\u003cp\u003eRare: psychotic disorder.\u003c\/p\u003e\n\u003cp\u003eRare: assault.\u003c\/p\u003e\n\u003cp\u003eRare: confusional state.\u003c\/p\u003e\n\u003cp\u003eRare: depression.\u003c\/p\u003e\n\u003cp\u003eRare: insomnia.\u003c\/p\u003e\n\u003cp\u003eVery rare: tic.\u003c\/p\u003e\n\u003cp\u003eNot known: euphoric behavior.\u003c\/p\u003e\n\u003cp\u003eVery rare: visual hallucination.\u003c\/p\u003e\n\u003cp\u003eNot known: suicidal behavior.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders:\u003c\/p\u003e\n\u003cp\u003eCommon: dizziness.\u003c\/p\u003e\n\u003cp\u003eCommon: headache.\u003c\/p\u003e\n\u003cp\u003eCommon: drowsiness.\u003c\/p\u003e\n\u003cp\u003eUncommon: restlessness.\u003c\/p\u003e\n\u003cp\u003eUncommon: paraesthesia.\u003c\/p\u003e\n\u003cp\u003eRare: convulsion.\u003c\/p\u003e\n\u003cp\u003eVery rare: dysgeusia.\u003c\/p\u003e\n\u003cp\u003eVery rare: syncope.\u003c\/p\u003e\n\u003cp\u003eVery rare: tremor.\u003c\/p\u003e\n\u003cp\u003eVery rare: dystonia.\u003c\/p\u003e\n\u003cp\u003eVery rare: dyskinesia.\u003c\/p\u003e\n\u003cp\u003eVery rare: cerebrovascular accidents (stroke)†\u003c\/p\u003e\n\u003cp\u003eNot known: amnesia.\u003c\/p\u003e\n\u003cp\u003eNot known: memory impairment.\u003c\/p\u003e\n\u003cp\u003eEye disorders:\u003c\/p\u003e\n\u003cp\u003eVery rare: accommodation disorder.\u003c\/p\u003e\n\u003cp\u003eVery rare: blurred vision.\u003c\/p\u003e\n\u003cp\u003eVery rare: oculogyric crisis.\u003c\/p\u003e\n\u003cp\u003eVery rare: swelling of the eyes.\u003c\/p\u003e\n\u003cp\u003eNot known: mydriasis.\u003c\/p\u003e\n\u003cp\u003eNot known: eye pain.\u003c\/p\u003e\n\u003cp\u003eNot known: vision impairment.\u003c\/p\u003e\n\u003cp\u003eNot known: photophobia.\u003c\/p\u003e\n\u003cp\u003eNot known: Ischemic optic neuropathy.\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders:\u003c\/p\u003e\n\u003cp\u003eNot known: dizziness.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders:\u003c\/p\u003e\n\u003cp\u003eUncommon: palpitations.\u003c\/p\u003e\n\u003cp\u003eRare: arrhythmia.\u003c\/p\u003e\n\u003cp\u003eRare: tachycardia.\u003c\/p\u003e\n\u003cp\u003eNot known: myocardial infarction†\u003c\/p\u003e\n\u003cp\u003eVascular pathologies:\u003c\/p\u003e\n\u003cp\u003eRare: paleness.\u003c\/p\u003e\n\u003cp\u003eRare: hypertension.\u003c\/p\u003e\n\u003cp\u003eVery rare: circulatory collapse.\u003c\/p\u003e\n\u003cp\u003eVery rare: hypotension.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders:\u003c\/p\u003e\n\u003cp\u003eVery rare: cough.\u003c\/p\u003e\n\u003cp\u003eUncommon: dyspnoea.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders:\u003c\/p\u003e\n\u003cp\u003eCommon: dry mouth.\u003c\/p\u003e\n\u003cp\u003eCommon: nausea.\u003c\/p\u003e\n\u003cp\u003eUncommon: diarrhoea.\u003c\/p\u003e\n\u003cp\u003eRare: vomiting.\u003c\/p\u003e\n\u003cp\u003eVery rare: ischemic colitis; Abdominal discomfort.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders:\u003c\/p\u003e\n\u003cp\u003eRare: Abnormal liver function (transaminases increased, alkaline phosphatase increased, gamma GT increased, blood bilirubin increased).\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders:\u003c\/p\u003e\n\u003cp\u003eUncommon: pruritus.\u003c\/p\u003e\n\u003cp\u003eUncommon: skin rash.\u003c\/p\u003e\n\u003cp\u003eRare: dry skin.\u003c\/p\u003e\n\u003cp\u003eRare: hyperhidrosis.\u003c\/p\u003e\n\u003cp\u003eRare: urticaria.\u003c\/p\u003e\n\u003cp\u003eVery rare: fixed drug eruption.\u003c\/p\u003e\n\u003cp\u003eVery rare: angioedema.\u003c\/p\u003e\n\u003cp\u003eVery rare: skin disease.\u003c\/p\u003e\n\u003cp\u003eVery rare: acute generalized exanthematous pustulosis.\u003c\/p\u003e\n\u003cp\u003ePathologies of the musculoskeletal system and connective tissue.\u003c\/p\u003e\n\u003cp\u003eNot known: arthralgia.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders:\u003c\/p\u003e\n\u003cp\u003eVery rare: enuresis.\u003c\/p\u003e\n\u003cp\u003eVery rare: dysuria.\u003c\/p\u003e\n\u003cp\u003eNot known: urinary retention.\u003c\/p\u003e\n\u003cp\u003eSystemic disorders and conditions relating to the administration site:\u003c\/p\u003e\n\u003cp\u003eCommon: weakness.\u003c\/p\u003e\n\u003cp\u003eUncommon: asthenia.\u003c\/p\u003e\n\u003cp\u003eUncommon: malaise.\u003c\/p\u003e\n\u003cp\u003eRare: edema.\u003c\/p\u003e\n\u003cp\u003eNot known: itching after withdrawal.\u003c\/p\u003e\n\u003cp\u003eMetabolism and nutrition disorders:\u003c\/p\u003e\n\u003cp\u003eRare: weight gain.\u003c\/p\u003e\n\u003cp\u003eReproductive system and breast disorders:\u003c\/p\u003e\n\u003cp\u003eNot known: erectile dysfunction.\u003c\/p\u003e\n\u003cp\u003e* Patient exposure was estimated from the calculation of sales data from IMS MIDAS. \u003csup\u003e†\u003c\/sup\u003eThese adverse reactions have been reported very rarely in post-marketing safety studies. A recent post-authorisation safety study (PASS) provided no evidence of an increased risk of myocardial infarction or cerebrovascular accident associated with the use of vasoconstrictors, including pseudoephedrine, for nasal decongestion. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSymptoms\u003c\/u\u003e In case of overdose the following may be observed: tachycardia, arrhythmias, hypertension, depressant or stimulant effects on the CNS. (sedation, apnea, collapse, insomnia, hallucinations, tremors, convulsions). These effects can be fatal. Symptoms observed after overdose of cetirizine are mainly associated with CNS effects or effects that might suggest an anticholinergic effect. Adverse events reported after taking at least 5 times the 10 mg dose of cetirizine are: confusion, diarrhea, dizziness, fatigue, headache, malaise, mydriasis, itching, restlessness, sedation, drowsiness, stupor, tachycardia, tremor and urinary retention. In case of overdose of pseudoephedrine, nausea, vomiting, mydriasis, anxiety, agitation, palpitations and reflex bradycardia may occur. Other possible effects are dysrhythmia, hypertensive crisis, intracerebral hemorrhage, myocardial infarction, psychosis, rhabbomyolysis, hypokalemia, and ischemic infarction of the intestine. In the case of overdose in children, drowsiness has been reported. Keep out of reach of children. In case of overdose, seek medical help or contact a poison control center immediately. \u003cu\u003eTreatment\u003c\/u\u003e Treatment, which should preferably take place in a hospital environment, must be symptomatic. If vomiting does not occur spontaneously it must be induced. Gastric lavage is recommended. There are no known antidotes. It is important to avoid the use of sympathomimetics. Hypertension can be controlled with α-blockers, possible tachycardia with β-blockers, convulsions with iv diazepam (or with diazepam administered rectally in the case of children). There is no specific antidote for cetirizine. Should overdose occur, symptomatic or supportive treatment is recommended. Following recent ingestion, gastric lavage is recommended. Cetirizine is not effectively eliminated by dialysis.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eREACTINE is contraindicated during pregnancy and breastfeeding. \u003cu\u003ePregnancy\u003c\/u\u003e Very little clinical data on pregnancies exposed to treatment are available for cetirizine. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonic\/foetal development, parturition or postnatal development. \u003cu\u003eBreastfeeding\u003c\/u\u003e Both cetirizine and pseudoephedrine are excreted in breast milk, therefore REACTINE should not be taken during breastfeeding. Cetirizine is excreted in breast milk at concentrations representing 25% to 90% of those measured in plasma, depending on the sampling time after administration.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCetirizine at recommended doses does not influence cognitive and motor functions; no effect on these abilities has been demonstrated with pseudoephedrine. However, due to its potential sedative action, caution should be exercised when driving or operating machinery. Objective measurements of driving ability, sleep latency and assembly line performance demonstrated no clinically relevant effects at the 10 mg dose of cetirizine. Patients intending to drive, engage in potentially dangerous activities or operate machinery should not exceed the dose of 10 mg of cetirizine and consider their response to the medicine. Patients should not drive, engage in potentially hazardous activities, or operate machinery if they feel drowsy or dizzy. In sensitive patients, concomitant use with alcohol or other CNS depressants may cause further reductions in alertness and impaired performance.\u003c\/p\u003e","brand":"Johnson \u0026 Johnson","offers":[{"title":"Default Title","offer_id":51730208719175,"sku":"032800043","price":8.78,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/johnson-johnson-spa-reactine-5-mg-120-mg-6-compresse-rilascio-prolungato-farmacia-dottor-tili-1213791071.jpg?v=1767154391","url":"https:\/\/www.dottortili.com\/en-eu\/products\/reactine-5-mg-120-mg-6-prolonged-release-tablets","provider":"Farmacia Dottor Tili","version":"1.0","type":"link"}